Epigenetics regulates gene expression in a reversible manner by chemically modifying DNA and histone proteins, which prevent permanent mutations or alterations within the genes or genome itself. Epigenetics is a study of change in the gene expression without any change in gene sequence. Epigenetic changes beyond a normal expression pattern can cause a variety of diseases. Epigenetic therapy involves use of drugs or other epigenome-influencing techniques to treat medical conditions including cancer, heart disease, diabetes, and mental illnesses. The global epigenetics drugs market growth mainly is driven by factors such as rising incidence of cancer, advancements in screening tools and huge sum invested in research and development activities. The impact of DNMT inhibitors is highly significant for inhibiting the cell cycle growth, and these inhibitors by their mechanism of action account for the major share of the global epigenetics drugs market.
The global epigenetics drugs market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug type (ChIP technology, DNA methylation), and their mechanism of action such as DNMT inhibitors – Azacitidine (vidaza) and Decitabine (dacogen); and HDAC inhibitors or HDIs – Romidepsin (istodax), Vorinostat (zolinza), and forecasts growth trends (CAGR% – 2017 to 2021).
The global epigenetics drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global epigenetics drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global epigenetics drugs market and included in this report are Celgene Corporation, Eisai Pharmaceuticals, Pharmacyclics Inc., Merck & Co Inc. and others.